lunes, 24 de octubre de 2016

Meningococcal Disease in US Military Personnel before and after Adoption of Conjugate Vaccine - Volume 22, Number 11—November 2016 - Emerging Infectious Disease journal - CDC

Meningococcal Disease in US Military Personnel before and after Adoption of Conjugate Vaccine - Volume 22, Number 11—November 2016 - Emerging Infectious Disease journal - CDC



Volume 22, Number 11—November 2016

Letter

Meningococcal Disease in US Military Personnel before and after Adoption of Conjugate Vaccine

To the Editor: In their recent letter (1), Broderick et al. provided useful information about the remarkable declines in incidence of meningococcal disease among active-duty US military personnel since the early 1970s, when meningococcal vaccination began within that population. The authors reported that the incidence of meningococcal disease from vaccine-covered serogroups was 0.183 cases/100,000 persons during 2006–2013 among persons vaccinated with quadrivalent conjugate meningococcal vaccine (MCV-4), compared with 0.307 cases/100,000 persons during 2000–2013 among persons vaccinated with quadrivalent polysaccharide meningococcal vaccine (MPSV-4). They stated that, because these rates did not differ significantly, case rates were similar in personnel vaccinated with MCV-4 and MPSV-4. Although statistically correct, this comment might mislead the unwary reader.
The absence of a significant difference does not necessarily mean that the 2 vaccines have similar effectiveness. The incidence rate of meningococcal disease was 68% higher ([0.307–0.183] × 100/0.183) during the period of MPSV-4 use than during the period of MCV-4 use. If the same findings arose in a study of sufficient size to achieve statistical significance, this difference would be considered of substantial clinical importance. A happy consequence of the long-term temporal trends in meningococcal incidence and the success of these vaccines is that the incidence of meningococcal disease is now sufficiently reduced that even the very large active-duty population is too small to provide the statistical power to declare these 2 different incidence rates as being statistically different.
The trends reported by Broderick et al. have continued. During 2006–2014, the incidence of meningococcal disease caused by vaccine-covered serogroups among US military recipients of MCV-4 fell to 0.146 per 100,000 person-years, whereas MPVS-4–related incidence did not change (M.P. Broderick, pers. comm.). Furthermore, through July 2016, the US military has not seen a case from a covered serogroup since 2011 among recipients of MCV-4. Even with these additional data, however, the difference between MCV-4 and MPSV-4 does not achieve statistical significance (M.P. Broderick, pers. comm.).
Michael D. DeckerComments to Author 
Author affiliation: Sanofi Pasteur, Swiftwater, Pennsylvania, USA; Vanderbilt University School of Medicine, Nashville, Tennessee, USA

Acknowledgment

The author is an employee of a company that manufactures both conjugate and polysaccharide meningococcal vaccines.

References

  1. Broderick MPPhillips CFaix DMeningococcal disease in US military personnel before and after adoption of conjugate vaccine. Emerg Infect Dis2015;21:3779.DOIPubMed
Suggested citation for this article: Decker MD. Meningococcal disease in US military personnel before and after adoption of conjugate vaccine [letter]. Emerg Infect Dis. 2016 Nov [date cited]. http://dx.doi.org/10.3201/eid2211.150498


DOI: 10.3201/eid2211.150498

No hay comentarios:

Publicar un comentario